Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (Children's Hospital, Zhejiang University School of Medicine)
- Development stage
- Unknown
- Lead developer
- Children's Hospital, Zhejiang University School of Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intratracheal
01
Overview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) is an investigational cell therapy being developed by The Children's Hospital of Zhejiang University School of Medicine for the treatment of severe bronchopulmonary dysplasia (BPD) in premature infants. The therapy involves the intratracheal administration of allogeneic MSCs harvested from human umbilical cord tissue (Wharton's jelly). These cells are hypothesized to exert therapeutic effects through paracrine mechanisms, secreting various growth factors and immunomodulatory cytokines that reduce lung inflammation, promote alveolarization, and improve pulmonary vascular development. This treatment aims to improve the survival rate and long-term respiratory outcomes for extremely preterm infants at high risk for chronic lung disease.
- Other names
- UC-MSCshUC-MSCsallogeneic human umbilical cord-derived mesenchymal stem cellsumbilical cord-derived mesenchymal stem cell transplantation
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (Children's Hospital, Zhejiang University School of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Children's Hospital, Zhejiang University School of Medicine).